| Peer-Reviewed

Medication-Related Osteonecrosis of the Jaws (MRONJ) Induced by Incompatible Complete Removable Denture: A Case Report

Received: 26 July 2017     Accepted: 12 September 2017     Published: 17 October 2017
Views:       Downloads:
Abstract

Multiple myeloma is a malignant, hematological neoplasia affected plasma cells. It causes anemia, leads to increased susceptibility to infections by compromising immune response and severe pain is raised as a result of osteolytic lesions. For medical therapy of this condition, bisphosphonates (BPs) can be prescribed. Despite its great benefits in Multiple Myeloma (MM), in particular intravenous administration of BPs can lead to Medication-related osteonecrosis of the jaws (MRONJ). A 61-year-old female patient refers to our department for complaint of difficulty on usage of her prosthesis. In medical history, it was learned that her chemotherapy for multiple myeloma has been continued for 5 years and skull radiographs showed characteristic punched-out lytic lesions. With clinical and radiological examinations, this condition diagnosed as Stage II MRONJ. The aim of this study is to report the case of MRONJ within the reason of incompatible prosthesis by this way to be directive about preventive management.

Published in International Journal of Clinical Oral and Maxillofacial Surgery (Volume 3, Issue 2)
DOI 10.11648/j.ijcoms.20170302.11
Page(s) 7-10
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Bisphosphonate-Related Osteonecrosis of the Jaw, Denture, Dental Prosthesis, Multiple Myeloma, Medication-Related Osteonecrosis of the Jaw, Osteonecrosis, Zoledronic Acid

References
[1] Parker, S. L., Davis, K. J., Wingo, P. A., Ries, L. A. G., & Heath, C. W. (1998). Cancer Statistics by Race and Ethnicity. A Cancer Journal for Clinicians, 48(1), 31–48. doi:10.3322/canjclin.48.1.31.
[2] Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Behrens, J. (2011). Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology, 154(1), 32–75. doi:10.1111/j.1365-2141.2011.08573.x.
[3] Gridelli, C. (2007). The use of bisphosphonates in elderly cancer patients. The Oncologist, 12, 62–71. doi:10.1634/theoncologist.12-1-62.
[4] Terpos, E., & Dimopoulos, M. (2005). Myeloma bone disease : pathophysiology and management, Annals of Oncology (May), 1223–1231. doi:10.1093/annonc/mdi235.
[5] Croucher, P. I. (1998). Bone disease in multiple myeloma. British Journal of Haematology, 103, 902–910. doi:10.1046/j.1365-2141.1998.01082.x
[6] Rugani, P., Acham, S., & Truschnegg, A. (2010). Bisphosphonate-associated osteonecrosis of the jaws : surgical treatment with ErCrYSGG-laser: case report. Oral Surgery, Oral medicine, Oral Pathology, Oral Radiology, and Endodontology, 110 (6), e1–e6. doi:10.1016/j.tripleo.2010.08.013.
[7] Durie, B. G. M., Kyle, R., Belch, A., Bensinger, W., Blade, J., Child, J. A., Webb, I. (n.d.). Myeloma management guıdelines a consensus report from the scientıfıc advisors of the international myeloma foundation. The Hematology Journal 4(6), 379-398. doi:10.1038/sj.thj.6200312.
[8] Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O’Ryan, F. (2014). American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. Journal of Oral and Maxillofacial Surgery, 72(10), 1938–1956. doi:10.1016/j.joms.2014.04.031.
[9] Peer, A., & Khamaisi, M. (2014). Diabetes as a risk factor for medication-related osteonecrosis of the jaw. Journal of Dental Research, 94(2), 252–260. doi:10.1177/0022034514560768.
[10] Allen, M. R., & Burr, D. B. (2009). The Pathogenesis of Bisphosphonate- Related Osteonecrosis of the Jaw : So Many Hypotheses, So Few Data. Journal of Oral and Maxillofacial Surgery. 67(5), 61–70. doi:10.1016/j.joms.2009.01.007.
[11] Saad, F., Brown, J., Van Poznak, C., Ibrahim, T., Stemmer, S., Stopeck, A., Dansey, R. (2012). of the jaw : integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology, 23, 1341–1347. doi:10.1093/annonc/mdr435.
[12] Andriani, A., Petrucci, M., Caravita, T., Montanaro, M., Villiva`, N., Levi, A., Gaglioti, D. (2012). Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom’s macroglobulinemia : a retrospective multicentric study. Blood Cancer Journal, 2, 1–4. doi:10.1038/bcj.2012.9.
[13] Yi, J. W., Lee, W., Kim, S., Heo, Y., Chae, D., & Lee, W. (2014). Effect of Zoledronate on the Expression of Vascular Endothelial Growth Factor-A by Articular Chondrocytes and Synovial Cells : An in Vitro Study. Journal of Bone Metabolism, 21(4), 249–255. doi:10.11005/jbm.2014.21.4.249.
[14] Bedogni, A., Bettini, G., Totola, A., Saia, G., & Nocini, P. F. (2010). Oral Bisphosphonate – Associated Osteonecrosis of the Jaw After Implant Surgery : A Case Report. Journal of Oral and Maxillofacial Surgery (02782391), 68(7), 1662–1666. doi:10.1016/j.joms.2010.02.037.
[15] Guarneri, V., Miles, D., Robert, N., Glaspy, J., Smith, I., Thomssen, C., Conte, P. (2010). Bevacizumab and osteonecrosis of the jaw : incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer, 181–188. doi:10.1007/s10549-010-0866-3.
[16] Hamadeh, I. S., Ngwa, B. A., & Gong, Y. (2015). Drug induced osteonecrosis of the jaw. Cancer Treatment Reviews, 41(5), 455–464. doi:10.1016/j.ctrv.2015.04.007.
[17] Bodem, J. P., Kargus, S., Engel, M., Hoffmann, J., & Freudlsperger, C. (2015). Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw. Journal of Cranio-Maxillofacial Surgery, 43(7), 1139–1143. doi:10.1016/j.jcms.2015.05.019.
[18] Diel, J. I., Fogelman, I., Al-Nawas, B., Hoffmeister, B., Migliorati, C., Gligorov, J., Aapro, M. S. (2007). Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw : Is there a diverse relationship of amino- and non-aminobisphosphonates?. 64(3), 198–207. doi:10.1016/j.critrevonc.2007.07.005.
[19] Campisi, G., Fede, O. Di, Musciotto, A., Casto, A. Lo, Muzio, L. Lo, Fulfaro, F., Gebbia, N. (2007). Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Annals of Oncology 18 (Supplement 6), 168–172. doi:10.1093/annonc/mdm250.
[20] Demirtaş, N., Aytuğar, E., Kazancıoğlu, H. O., & Erdoğan, E. B. (2015). Multiple myelomalı hastada dental yaklaşım: olgu sunumu. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, 10, 46–50. doi:10.17567/dfd.93639.
Cite This Article
  • APA Style

    Gelengül Gürbüz-Urvasızoğlu, Nesrin Saruhan, Mert Ataol. (2017). Medication-Related Osteonecrosis of the Jaws (MRONJ) Induced by Incompatible Complete Removable Denture: A Case Report. International Journal of Clinical Oral and Maxillofacial Surgery, 3(2), 7-10. https://doi.org/10.11648/j.ijcoms.20170302.11

    Copy | Download

    ACS Style

    Gelengül Gürbüz-Urvasızoğlu; Nesrin Saruhan; Mert Ataol. Medication-Related Osteonecrosis of the Jaws (MRONJ) Induced by Incompatible Complete Removable Denture: A Case Report. Int. J. Clin. Oral Maxillofac. Surg. 2017, 3(2), 7-10. doi: 10.11648/j.ijcoms.20170302.11

    Copy | Download

    AMA Style

    Gelengül Gürbüz-Urvasızoğlu, Nesrin Saruhan, Mert Ataol. Medication-Related Osteonecrosis of the Jaws (MRONJ) Induced by Incompatible Complete Removable Denture: A Case Report. Int J Clin Oral Maxillofac Surg. 2017;3(2):7-10. doi: 10.11648/j.ijcoms.20170302.11

    Copy | Download

  • @article{10.11648/j.ijcoms.20170302.11,
      author = {Gelengül Gürbüz-Urvasızoğlu and Nesrin Saruhan and Mert Ataol},
      title = {Medication-Related Osteonecrosis of the Jaws (MRONJ) Induced by Incompatible Complete Removable Denture: A Case Report},
      journal = {International Journal of Clinical Oral and Maxillofacial Surgery},
      volume = {3},
      number = {2},
      pages = {7-10},
      doi = {10.11648/j.ijcoms.20170302.11},
      url = {https://doi.org/10.11648/j.ijcoms.20170302.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcoms.20170302.11},
      abstract = {Multiple myeloma is a malignant, hematological neoplasia affected plasma cells. It causes anemia, leads to increased susceptibility to infections by compromising immune response and severe pain is raised as a result of osteolytic lesions. For medical therapy of this condition, bisphosphonates (BPs) can be prescribed. Despite its great benefits in Multiple Myeloma (MM), in particular intravenous administration of BPs can lead to Medication-related osteonecrosis of the jaws (MRONJ). A 61-year-old female patient refers to our department for complaint of difficulty on usage of her prosthesis. In medical history, it was learned that her chemotherapy for multiple myeloma has been continued for 5 years and skull radiographs showed characteristic punched-out lytic lesions. With clinical and radiological examinations, this condition diagnosed as Stage II MRONJ. The aim of this study is to report the case of MRONJ within the reason of incompatible prosthesis by this way to be directive about preventive management.},
     year = {2017}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Medication-Related Osteonecrosis of the Jaws (MRONJ) Induced by Incompatible Complete Removable Denture: A Case Report
    AU  - Gelengül Gürbüz-Urvasızoğlu
    AU  - Nesrin Saruhan
    AU  - Mert Ataol
    Y1  - 2017/10/17
    PY  - 2017
    N1  - https://doi.org/10.11648/j.ijcoms.20170302.11
    DO  - 10.11648/j.ijcoms.20170302.11
    T2  - International Journal of Clinical Oral and Maxillofacial Surgery
    JF  - International Journal of Clinical Oral and Maxillofacial Surgery
    JO  - International Journal of Clinical Oral and Maxillofacial Surgery
    SP  - 7
    EP  - 10
    PB  - Science Publishing Group
    SN  - 2472-1344
    UR  - https://doi.org/10.11648/j.ijcoms.20170302.11
    AB  - Multiple myeloma is a malignant, hematological neoplasia affected plasma cells. It causes anemia, leads to increased susceptibility to infections by compromising immune response and severe pain is raised as a result of osteolytic lesions. For medical therapy of this condition, bisphosphonates (BPs) can be prescribed. Despite its great benefits in Multiple Myeloma (MM), in particular intravenous administration of BPs can lead to Medication-related osteonecrosis of the jaws (MRONJ). A 61-year-old female patient refers to our department for complaint of difficulty on usage of her prosthesis. In medical history, it was learned that her chemotherapy for multiple myeloma has been continued for 5 years and skull radiographs showed characteristic punched-out lytic lesions. With clinical and radiological examinations, this condition diagnosed as Stage II MRONJ. The aim of this study is to report the case of MRONJ within the reason of incompatible prosthesis by this way to be directive about preventive management.
    VL  - 3
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Eski?ehir Osmangazi University, Eski?ehir, Turkey

  • Department of Oral and Maxillofacial Surgery Faculty of Dentistry, Ataturk University, Erzurum, Turkey

  • Sections